Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(9):570-571; doi:10.1093/jnci/djj184
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Grann, V. R.
Right arrow Articles by Muggia, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grann, V. R.
Right arrow Articles by Muggia, F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

EDITORIAL

Completion Rates of Adjuvant Chemotherapy for Colon Cancer: A Historical Perspective

Victor R. Grann, Franco M. Muggia

Affiliations of authors: Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Departments of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (VRG); New York University School of Medicine and the Cancer Institute, New York, NY (FMM)

Correspondence to: Franco M. Muggia, MD, New York University School of Medicine, Kaplan Comprehensive Cancer Center, 550 First Ave., New York, NY 10016 (e-mail: franco.muggia@med.nyu.edu).

The first 10% of the full text of this article appears below.

The impact of adjuvant therapy on cancer survival is one of our most important recent achievements in medical oncology. This milestone has been accomplished through the use of clinical trials especially among patients with breast and colon cancer. The annual odds of death from breast cancer alone among patients in these trials has decreased by up to 28%, depending on the criteria used for patient enrollment, the types of treatment given, and the characteristics of the tumors themselves (1). Similar, but less well-defined, results have been reported for colon cancer (2–5).

Randomized clinical trials provide us with the strongest evidence of efficacy . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?